either ACE or ARNI. We also know about some of the diabetic medications that have now been shown to improve outcomes in heart failure patients. So we have a lot of medication in the toolbox.

The PARADIGM-HF and PARAGON-HF trials demonstrated consistent benefits of sacubitril/valsartan relative to RAS inhibitors in ...

Scarring of heart tissue can be slowed but not stopped, and can lead to heart failure. But a new study has shown that an ...

Medscape Business of Medicine, August 14, 2015 PVCs: Modifiable Risk Factor for Heart Failure . . . Maybe ... adherent adopter of the new ARNI heart failure drug. theheart.org on Medscape, August ...

Standing Desks Don’t Cut Stroke or Heart Failure RiskNew research suggests that using a standing desk doesn’t reduce the chance of problems like heart disease or stroke, and may even boost the ...

A study by researchers at Saint Louis University shows that only one in eight patients with heart failure in the United ...

Systolic congestive heart failure, or systolic heart failure, is a type of heart failure that involves the left side of the heart. As the left side of the heart begins losing some function ...

Experimental Drug Engineered to Prevent Heart Failure After Heart Attacks Oct. 24, 2024 — An experimental therapeutic monoclonal antibody therapy could become the first to directly enhance ...

Cardiovascular disease remains the foremost cause of morbidity and mortality globally, affecting millions of individuals. Recent discoveries illuminate the substantial role of genetics in ...

Serum FGF21 Levels Are Related to Atherosclerosis in T2D A new study examines the relationship between serum FGF21 levels and subclinical atherosclerosis in patients with type 2 diabetes ...

“We’ve lost our traction on mitigating the risk for cardiovascular disease in general, but particularly for heart failure, the trio of hypertension, obesity, and diabetes, all accelerated by ...